Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) Equity Average (2023 - 2025)

Mangoceuticals' Equity Average history spans 3 years, with the latest figure at $15.5 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 11.36% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.5 million, a 11.36% increase, with the full-year FY2025 number at $14.6 million, up 98.0% from a year prior.
  • Equity Average hit $15.5 million in Q4 2025 for Mangoceuticals, down from $17.5 million in the prior quarter.
  • Over the last five years, Equity Average for MGRX hit a ceiling of $19.7 million in Q2 2025 and a floor of -$91857.0 in Q1 2024.
  • Historically, Equity Average has averaged $9.4 million across 3 years, with a median of $10.1 million in 2024.
  • Biggest five-year swings in Equity Average: crashed 104.14% in 2024 and later skyrocketed 18713.56% in 2025.
  • Tracing MGRX's Equity Average over 3 years: stood at $1.1 million in 2023, then soared by 1204.21% to $13.9 million in 2024, then increased by 11.36% to $15.5 million in 2025.
  • Business Quant data shows Equity Average for MGRX at $15.5 million in Q4 2025, $17.5 million in Q3 2025, and $19.7 million in Q2 2025.